Pasithea Clinics
Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities,
Expanding its International Footprint
-- Pasithea Clinics to offer ketamine infusion therapy for
the treatment of mental health disorders --
-- First mobile clinics
launch in New York City, Los Angeles, San Diego, and
San Francisco, with expansion to additional U.S. cities in coming
months --
-- Treatments conducted by board-certified medical
professionals --
Miami Beach, FL / November 17, 2021 -- InvestorsHub
NewsWire -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders, today announced that its wholly owned subsidiary,
Pasithea Clinics, commenced clinical operations, offering in-home
intravenous ("IV") ketamine therapy to patients suffering from
treatment-resistant mental health issues. Initially, the treatment
will be offered in New York City, Los Angeles, San Diego, and San
Francisco and will expand nationwide in the coming
months.
"The need for more effective treatment options for patients
with mental health disorders has never been greater. Ketamine, when
used at sub-anesthetic doses, has been shown to be highly effective
in treating some psychiatric disorders. Still, we need to broaden
access to this treatment to a larger patient population in a safe
and convenient way. Through our mobile clinics, patients benefit
from receiving the ketamine therapy in the privacy and comfort of
their own homes. With patient safety as our top priority, all
ketamine treatments will be delivered by board-certified medical
professionals. This launch is an important stepping stone in
expanding our international footprint in this space," stated Dr.
Tiago Reis Marques, CEO of Pasithea Therapeutics.
Patients with mental health disorders often struggle to
complete day-to-day activities, and even small tasks can take extra
effort. In disorders such as depression and post-traumatic stress
disorder, symptoms such as fatigue, social isolation, lack of
motivation, and high levels of anxiety are frequent. The effort to
go to a physical clinic can be overwhelming. By providing this
treatment at the patient's home, Pasithea aims to broaden access to
this important therapy.
"We are pleased to commence our U.S. rollout
in major
cities in New York and California, with plans to scale our business
in other cities over the coming months. Although ketamine is a very
safe drug to administer, there are still some risks. Patient safety
is of paramount importance, and we are providing a network of
highly trained medical professionals to administer this treatment
in the comfort of the patient´s home. Our medical team ensures that
our patients receive state of the art support throughout their
treatment experience. We believe
we can become the best-in-class and largest provider
of IV ketamine treatments in the United States. We will use our
at-home model to expand our reach in the U.S. in a fast and
accessible way," said Dr. Adam Nadelson,
Managing Director of Pasithea Clinics in the United
States.
Ketamine is a U.S. Food and Drug Administration ("FDA")
approved drug introduced to the medical community as an anesthetic
more than 50 years ago. It has recently been repurposed for the treatment of
psychiatric disorders using significantly lower doses than in
anesthesia and is now gaining ground as a promising
treatment for mental health disorders. In certain psychiatric conditions, such as
treatment-resistant depression ("TRD") and post-traumatic stress
disorder ("PTSD"), it has shown remarkable efficacy and a rapid and
sustained effect, and up to 70% of those who receive
this treatment can eventually show a clinical response. While the
number of treatments suggested is done on a case-by-case
basis, a typical treatment plan
consists of up to six infusions in the interval of two to three
weeks.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S. biotechnology
company focused on the research and discovery of new and effective
treatments for psychiatric and neurological disorders. With an
experienced team of experts in the fields of neuroscience and
psychopharmacology, Pasithea is developing new molecular entities
for the treatment of psychiatric and neurological disorders.
Pasithea is also focused on addressing the needs of patients
currently suffering with mental illness by providing access to IV
ketamine infusions both in clinics and in-home settings.
Forward Looking
Statements
This press release contains statements that constitute
"forward-looking statements." Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company's filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis
Marques
Chief Executive
Officer
E:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M.
Wilson
In-Site
Communications, Inc.
T:
212-452-2793
E:
lwilson@insitecony.com